

Please join us on Day 1, October 15<sup>th</sup> in the Constitution Ballroom of the Grand Hyatt.

	DAY 1 - TUESDAY, OCTOBER 15 <sup>TH</sup>				
TIME	CONTENT				
8:20-10:15	<ul> <li>HHS Executive Welcome – Secretary Alex M. Azar II</li> <li>ASPR Welcome – Dr. Robert Kadlec</li> <li>Industry Partner Featured Speakers – Dr. Julie Gerberding and Raul Brizuela</li> </ul>				
	BREAK				
10:30-12:00	<ul> <li>US Government Partner Featured Speaker – Dr. Janet Woodcock</li> <li>State of BARDA, Director's Address – Dr. Rick Bright</li> <li>Chemical, Biological, Radiological, and Nuclear Updates – Dr. Chris Houchens</li> <li>Influenza and Emerging Infectious Diseases Updates – Dr. Robert Johnson</li> </ul>				
	LUNCH				
1:15-2:45	<ul> <li>Industry Partner Featured Speaker – Cat Oyler</li> <li>Division of Research, Innovation, &amp; Ventures Updates – Dr. Gary Disbrow</li> <li>Division of Contracts Management &amp; Acquisition Updates – Joffrey Benford</li> </ul>				
BREAK					
3:00-5:00	<ul> <li>Division of Clinical Development – Dr. Robert Walker</li> <li>Division of Detection, Diagnostics, and Devices – Rodney Wallace</li> <li>Division of Non-Clinical Development – Dr. Clay Hughes</li> <li>Division of Pharmaceutical Countermeasures Infrastructure – Michael Angelastro</li> <li>Division of Regulatory and Quality Affairs Updates – Dr. Tremel Faison</li> <li>Quickfire Challenge Winner Announced and Fireside Chat</li> <li>Closing</li> </ul>				

## **EVENT SCHEDULE**

Please join us for sessions on Day2 in the Grand Hyatt and Marriott at Metro Center

		DAY 2 - WEDNESDAY, OCTOBER 16 <sup>TH</sup>					
TIME	Marriott Salon 1	<b>Marriott</b> Salon 2	<b>Marriott</b> Salon 3	Grand Hyatt Declaration	<b>Grand Hyatt</b> Penn Quarter	<b>Grand Hyatt</b> Networking	
9:00				WELCOME VIDEO			
9:00- 10:30	Antibacterial, Antiviral & Antitoxin, & Vaccine MCMs Against Biological CBRN Threats		Developing Nonclinical Models with Partners	Lightning Talks (schedule on page 3)	Diagnostics & Devices: The Other MCM	<ul> <li>Networking</li> <li>Pandemic Influenza (white)</li> <li>Division of Contracts Mgmt and Acquisition (gray)</li> <li>Division of Clinical Development (blue)</li> <li>Division of Reg. &amp; Quality Affairs (black)</li> </ul>	
				BREAK			
10:45- 12:00	New Opportunities to Develop & Sustain MCMs for Influenza		AMED: the Japan Agency for Medical Research & Development	The Division of Research, Innovation, & Ventures: Catalytic Approaches to Health Security	BARDA Contracting	Networking	
				LUNCH			
1:30- 2:45	Conducting Clinical Trials During an Outbreak: What it Takes to be Successful	DoD - BARDA Partnership Panel	Countering the Unknown: CBRN Threats and Emerging Infectious Diseases	Leveraging Public- Private Collaborations for Pandemic Influenza Preparedness	Addressing the Failing Commercial Market for New Antimicrobial Products	Networking  CBRN Physical Threats (white)  Division of Contracts Mgmt and Acquisition (gray)  Division of Research, Innovation, & Ventures (black)  Division of Non-Clinical Dev. (blue)	
				BREAK			
3:00- 4:15	Regulatory Considerations in MCM Development	Biodefense Strat. & PAHPAIA: What Recent Changes Mean for BARDA's Stakeholders	ASPR Next	MCMs Against Thermal Burn, Chemical, Radiological & Nuclear Threats	Lightning Talks (schedule on page 3)	<ul> <li>Networking</li> <li>Influenza Adv. Research &amp; Dev. (white)</li> <li>Antimicrobial Resistance (gray)</li> <li>Division of Detection, Diagnostics, &amp; Devices Infrastructure (black)</li> </ul>	

## **EVENT SCHEDULE**

Please join us in the Grand Hyatt Declaration room for the Wednesday October 16<sup>th</sup> morning Lightning Talk Presentations

WEDNESDAY OCTOBER 16 <sup>TH</sup> , 9:00 – 10:30 AM - LIGHTNING TALKS					
CritiTech Particle Engineering Solutions	Next-Gen Pulmonary MCMs Enabled by Supercritical Precipitation Technology				
DEINOVE	DNV3837/DNV3681, a novel class of quinolonyl-oxazolidinone antibacterials targeting both urgent threats to public health and bioterrorism pathogens				
Dynocardia, Inc	First, Standalone, Wearable Vital Signs Monitor for Controlling Emerging Infectious Diseases Outbreaks				
Fluid-Screen	Fluid-Screen: Real-Time Microbial Detection for Biomanufacturing				
Foenestra Corporation	Solid State Nanopore-Based Sequence Detection Platform				
Inflammatix, Inc.	HostDx Endotypes: sepsis immunotherapy prediction				
Invirsa	INV-102 Shows Unique Promise to Treat Ocular Sulfur Mustard Gas Injury				
KLOX Technologies Inc.	Fluorescent Light Energy-Induced Biomodulation For The Management Of Burn Injuries: Acting At A Cellular Level To Control Inflammation And Improve Healing				
Myelo Therapeutics GmbH	Myelo001 as an Orally Applied Treatment of Acute Radiation Syndrome				
Phagelux Inc.	Field Deployable Bacteriophage Solutions for the Prevention and Treatment of Multidrug Resistant Infections				
Crossject	Emergency needle free auto-injector				

Please join us in the Grand Hyatt Penn Quarter room for the Wednesday October 16<sup>th</sup> afternoon Lightning Talk Presentations

WEDNESDAY OCTOBER 16 <sup>TH</sup> , 3:00 – 4:15 PM - LIGHTNING TALKS PRESENTED BY					
CanaryQ	Sample Handling for the Untrained User; No Mail-In Required				
DermiSense Inc	Enabling the Presymptomatic Detection of Infection with Zero-Power Test Strips				
Karius, Inc.	Karius Test Enabling Precision Medicine for Infectious Diseases				
RenovaCare, Inc.	Stem Cell Therapies for Thermal, Chemical, & Radiation Burns				
Scanogen Inc.	Point-of-care Molecular Detection of Bacterial Pathogens with Culture Level Sensitivity				
Terumo BCT	Future Generation Pathogen Reduction Technology				
Univercells S.A.	NevoLine Intensified, Integrated Vaccine Manufacturing Platform for MCM				
University of Notre Dame	Phage-Mimicking, Broad-Spectrum, Antibacterial Nanoparticles				
Vaxxas	Micro Array Patch for Pandemic Influenza Vaccine				